TROX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TROX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and does not want to wait for a better entry. The stock is under clear pressure from negative analyst revisions, weakening titanium dioxide fundamentals, and weak price momentum. While the options market shows a bullish call-skew, the overall setup does not support an immediate buy. Best direct call: hold, not buy.
The technical picture is weak. TROX is trading at 8.145, below the pivot level of 9.264 and near the first support at 8.331, with the next support at 7.756. MACD histogram is -0.228 and worsening, which confirms bearish momentum. RSI_6 at 30.808 is near oversold but not a strong reversal signal yet. Moving averages are converging, so trend direction is not strong enough to confirm a durable rebound. Near-term stock pattern data suggests only modest upside expectations, with a 60% chance of -0.07% next day, 2.36% next week, and 8.41% next month.
["Options positioning is heavily call-skewed, which reflects bullish trader sentiment.", "The stock has already seen strong year-to-date momentum, which can support short-term interest.", "Some analyst targets remain around $9, which is slightly above the current price."]
["Goldman Sachs downgraded TROX from Buy to Sell and highlighted worsening TiO2 fundamentals.", "Chinese TiO2 export volumes came in stronger than expected, increasing competitive pressure.", "U.K. antitrust approval for LB Group's purchase of the Greatham TiO2 facility adds more supply/competition risk in Europe.", "Consensus EBITDA estimates have fallen materially, pointing to weaker forward earnings expectations.", "The stock is trading with bearish momentum and is below key pivot resistance."]
No usable latest-quarter financial snapshot was provided because the financial data section returned an error. That said, the available analyst commentary indicates deteriorating earnings expectations, with consensus EBITDA estimates down 18% and 3% in recent updates. For a long-term beginner investor, that weakening forward growth picture is a negative.
Analyst sentiment has turned negative over the past month. Goldman Sachs downgraded Tronox to Sell from Buy with a $9 target, Fermium Research downgraded to Hold from Buy with a $9 target, Truist downgraded to Sell from Hold with an $8 target, and Mizuho remains Underperform with a lower target. UBS is the only relatively neutral voice, keeping Neutral with a $9 target. Overall Wall Street view: more cons than pros, with downside concerns around TiO2 demand, pricing, and margins dominating.
